Cargando…
The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
There is a plethora of published cancer biomarkers but the reality is that very few, if any, new circulating cancer biomarkers have entered the clinic in the last 30 years. I here try to explain this apparent oxymoron by classifying circulating cancer biomarkers into three categories: fraudulent rep...
Autor principal: | Diamandis, Eleftherios P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425158/ https://www.ncbi.nlm.nih.gov/pubmed/22876833 http://dx.doi.org/10.1186/1741-7015-10-87 |
Ejemplares similares
-
Melanoma overdiagnosis: why it matters and what can be done about it
por: Bell, Katy J.L., et al.
Publicado: (2022) -
Addressing men's health policy concerns in Australia: what can be done?
por: Smith, James A
Publicado: (2007) -
COVID-19 in Iran: What was done and what should be done
por: Nojomi, Marzieh, et al.
Publicado: (2021) -
Khat Use: What Is the Problem and What Can Be Done?
por: Omar, Yusuf Sheikh, et al.
Publicado: (2015) -
What neuroscience has already done for us: Commentary on… Why hasn't neuroscience delivered for psychiatry?
por: Sinclair, Lindsey Isla
Publicado: (2020)